Max Jaderberg, president of AI drug discovery company Isomorphic Labs, recently stated that all future drugs will be designed by AI, and the company hopes to accelerate this process. The company was spun out of DeepMind in 2021 by Nobel laureate Demis Hassabis and is part of Google parent company Alphabet. It is currently in the preclinical stage of drug development and expects to launch its first clinical trial by the end of 2026, focusing on areas such as cancer, immune system diseases, and inflammation, using a business model that combines in-house development with external partnerships. Its core technology is the unified drug design engine IsoDDE, disclosed in February 2026, which outperforms AlphaFold 3 on multiple key metrics, can cover more stages of drug design, and reduces trial and error in R&D. The company has raised about $2.7 billion to date and is advancing a new round of financing negotiations, with an estimated valuation that could reach $40 billion or even higher. Jaderberg said the company is still in an early stage of development, and the upcoming first clinical trial will be a key test of its AI drug R&D results.